- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01959178
A Study to Evaluate a Mid Add Multi-Focal Soft Contact Lens
September 9, 2020 updated by: Bausch & Lomb Incorporated
This study is to evaluate the product performance of the investigational LD127025 MF mid add soft contact lens compared to CIBA Vision's Air Optix Aqua MF MED add soft contact lenses when used among currently adapted soft contact lens wearers.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
146
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
Rochester, New York, United States, 14609
- Bausch & Lomb Incorporated
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria
- Have physiologically normal anterior segments not exhibiting biomicroscopy findings Grade 2 or greater and/or presence of infiltrates.
- Be adapted wearers of soft contact lenses, wear a lens in each eye, and each lens must be of the same manufacture and brand.
- Be correctable through spherocylindrical refraction to 42 letters (0.1 logMAR) or better (distance, high contrast) in each eye.
- Require contact lens correction from -5.00 D to +3.00 D in each eye.
- Be Presbyopic and require near add correction from +1.00 D to +1.75 D in each eye.
- Be an adapted monovision soft contact lens wearer or multifocal soft contact lens wearer or an adapted spherical soft contact lens wearer who also uses spectacles for near vision correction.
- Be willing to use a lens care system as required by the lens replacement schedule.
- Has a distance spherical equivalent refraction between -5.50 D and +3.00 D.
Exclusion Criteria:
- Not correctable to 32 letters (0.3 logMAR) in each eye with soft spherical contact lenses.
- Participated in any drug or device clinical investigation (within 14 days) prior to entry into this study and/or during the period of study participation.
- Women of childbearing potential if one of the following: pregnant, plans to become pregnant during study, is breast-feeding.
- Any Grade 2 or greater finding during the slit lamp examination. Subjects with corneal infiltrates of ANY GRADE are not eligible.
- Any scar or neovascularization within the central 4mm of the cornea. Subjects with minor peripheral corneal scarring (that does not extend into the central area), that in the Investigator's judgment, does not interfere with contact lens wear, are eligible for this study.
- Any "Present" finding during the slit lamp examination that, in the Investigator's judgment, interferes with contact lens wear.
- Anisometropia (spherical equivalent) of greater than 2.00 D.
- Aphakic.
- Amblyopic.
- Allergic to any component in the study care products.
- Meet any of the following criteria:
- Ophthalmologist, OD, Optician, Ophthalmologist's Assistant/Technician
- employee of a market research firm
- employee of manufacturer of contact lens or contact lens care products
- Ocular astigmatism of greater than 1.00 D in either eye.
- Have had any corneal surgery (ie, refractive surgery).
- Toric contact lens wearer.
- Have worn gas permeable (GP) contact lenses within the last 30 days or PMMA lenses within the last 3 months.
- Have an active ocular disease or are using any ocular medication.
- Have any systemic disease currently affecting ocular health or which, in the Investigator's opinion, may have an effect on ocular health during the course of the study.
- Using any systemic medications that will, in the Investigator's opinion, affect ocular physiology or lens performance.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: LD127025 MF
Mid add daily disposable soft contact lens worn on a daily wear basis for 1 week.
|
At Visit 1, one-half of the subjects will be randomized to receive the investigational soft contact lens, after approximately one week of wearing the first lens type, the subjects will return for the 1-Week Crossover Visit (Visit 2) for an exam, and to determine if the subject remains eligible to continue in the next phase of the study with the control soft contact lens.
At Visit 1, one-half of the subjects will be randomized to receive the control soft contact lens, after approximately one week of wearing the first lens type, the subjects will return for the 1-Week Crossover Visit (Visit 2) for an exam, and to determine if the subject remains eligible to continue in the next phase of the study with the investigational soft contact lens.
|
|
Active Comparator: Air Optix Aqua MF
Medium add daily disposable soft contact lens worn on a daily wear basis for one week.
|
At Visit 1, one-half of the subjects will be randomized to receive the investigational soft contact lens, after approximately one week of wearing the first lens type, the subjects will return for the 1-Week Crossover Visit (Visit 2) for an exam, and to determine if the subject remains eligible to continue in the next phase of the study with the control soft contact lens.
At Visit 1, one-half of the subjects will be randomized to receive the control soft contact lens, after approximately one week of wearing the first lens type, the subjects will return for the 1-Week Crossover Visit (Visit 2) for an exam, and to determine if the subject remains eligible to continue in the next phase of the study with the investigational soft contact lens.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean Visual Acuity
Time Frame: At 1 Week follow up
|
Visual acuity was assessed by distance high contrast logarithm of the minimum angle of resolution (logMAR).
|
At 1 Week follow up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Symptoms/Complaints
Time Frame: At 1 Week follow up
|
Symptoms/complaints were assessed on a scale from 0 to 100, with 0 denoting unfavorable symptoms/complaints.
|
At 1 Week follow up
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Robert Stefffen, Bausch & Lomb Incorporated
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2013
Primary Completion (Actual)
July 1, 2013
Study Completion (Actual)
August 1, 2013
Study Registration Dates
First Submitted
October 8, 2013
First Submitted That Met QC Criteria
October 8, 2013
First Posted (Estimate)
October 9, 2013
Study Record Updates
Last Update Posted (Actual)
September 30, 2020
Last Update Submitted That Met QC Criteria
September 9, 2020
Last Verified
September 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 825E
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Presbyopia
-
Ohio State UniversityRecruitingPresbyopia | Presbyopia CorrectionUnited States
-
Bruno Vision Careiuvo BioScience Operations, LLCCompleted
-
Johnson & Johnson Vision Care, Inc.CompletedPresbyopia CorrectionUnited Kingdom
-
VIS, Inc.Active, not recruitingPresbyopia Correction
-
AST Products, Inc.CompletedCataract | Presbyopia CorrectionSpain
-
IROC AGAMO IrelandActive, not recruitingCataract | Presbyopia CorrectionSwitzerland
-
Bausch & Lomb IncorporatedCompletedMyopia and Hyperopia and PresbyopiaUnited States
-
Technolas Perfect Vision GmbHUnknownHyperopic PresbyopiaIreland
-
The Hong Kong Polytechnic UniversityNot yet recruitingPresbyopia | Presbyopia Correction
-
University Eye Hospital SvjetlostCompletedCataract | Visual Acuity | Presbyopia CorrectionCroatia
Clinical Trials on LD127025 MF
-
Tokat Gaziosmanpasa UniversityCompleted
-
Epirium Bio Inc.CompletedHealthy VolunteersUnited States
-
Purdue UniversityRecruitingHealthy VolunteersUnited States
-
Purdue UniversityUniversity of OregonRecruitingHealthy VolunteersUnited States
-
CooperVision, Inc.Completed
-
Campus Bio-Medico UniversityUniversity of Rome Tor Vergata; University Hospital of Ferrara; Arcispedale Santa... and other collaboratorsTerminatedIschemic Stroke | Stroke, AcuteItaly
-
VA Office of Research and DevelopmentRecruitingDepression | Anxiety | Post Traumatic Stress Disorder (PTSD)United States
-
Alcon ResearchCompleted
-
Alcon ResearchCompletedRefractive Error | Presbyopia
-
National Taiwan University HospitalUnknownSecondary Malignant Neoplasm of SpineTaiwan